Trial intelligence / Profile preview

EMBOLD Sarcoma-202: Risvutatug Rezetecan in Previously Treated Advanced Sarcomas

2025-523997-18-00Phase 2Authorised

Sponsor: GSK
Start: May 2026
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Countries: 6

Overview

Phase 2 trial of risvutatug rezetecan in osteosarcoma (OS) and soft tissue sarcoma (STS) (2 cohorts), sponsored by GSK. Primary endpoints: Progression-free survival rate at week 18 (PFS18) and Confirmed objective response rate (ORR). Planned start May 2026; status: authorised.

Drugs

risvutatug rezetecan

Conditions

osteosarcoma (OS)soft tissue sarcoma (STS)

Beyond the preview

Go deeper on 2025-523997-18-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2025-523997-18-00.